MicroPort<sup>®</sup> Attends GW-ICC 2016

Beijing, China –From October 13 to October 16, the 27th Great Wall International Congress of Cardiology ("GW-ICC 2016"), the 21st Annual Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy ("ISCP"), International Congress of Cardiovascular Prevention and Rehabilitation 2016, the World Heart Failure Congress 2016 and Asia Pacific Heart Congress 2016 were held in China National Convention Center, with 17300 medical professionals in attendance. On October 14, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the GW-ICC 2016, and hosted a symposium - "Chasing the Horizon: Integrated Cardiac Intervention Platform by MicroPort®", which attracted wide attention from the audience.
 
Professor Changsheng Ma, Chairman of GW-ICC 2016 and Chief Physician of Beijing Anzhen Hospital of Capital Medical University, Professor Shubin Qiao of Fuwai Hospital of Chinese Academy of Medical Science, Professor Jiefu Yang of Beijing Hospital, and Professor Hengliang Wang of Puyang Oilfield General Hospital were invited as chairmen of the MicroPort® symposium. Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Science and Professor Wenzhi Pan of Zhongshan Hospital of Fudan University were invited as key-note speakers to share the latest design concept and clinical research results of MicroPort® innovative products such as Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®").
 
The MicroPort® symposium started with a speech by Professor Bo Xu – "Innovation in Intervention: From Firehawk® to Firesorb™", in which he introduced in detail the design structure and innovative concept of MicroPort® in-house developed Firehawk® and Firesorb™ Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb™"), the second-generation fully bioresorbable scaffold, and noted that the six-month follow-up data of Firesorb™ FUTURE I Clinical Trial will be released on Transcatheter Cardiovascular Therapeutics 2016.
 
Themed on "Clinical Trial of VitaFlow™ Transcatheter Aortic Valve and Delivery System ("VitaFlow™")", Professor Wenzhi Pan Shared the 30-day follow-up results of VitaFlow™ large-scale clinical trial with 86 patients, including low incidence rate of adverse cases, exceptional valve performance,to further prove the safety and efficacy of MicroPort® VitaFlow™.
 
Afterwards, Professor Jianzeng Dong, director of the First Affiliated Hospital of Zhengzhou University and associate director of cardiology department center from Beijing Anzhen Hospital, Capital Medical University, delivered a speech on "Clinical Trial of Columbus® 3D EP Navigation System ("Columbus®")". He said, the domestically developed Columbus® and its mapping catheter pioneer in the china market to offer physicians with a comprehensive solution for complex arrhythmias, and they would help lower the cost of procedures. As its clinical trial outcome achieves desired results, Columbus® is expected to benefit more patients with atrial fibrillation.
 
In the end, MicroPort® Chief Technology Officer Dr. Qiyi Luo focused on the theme "Chasing the Horizon: Integrated Cardiac Intervention Platform by MicroPort®" to summarize the innovation path of MicroPort® in terms of the development of its coronary stents, transcatheter aortic valves, electrophysiology devices and pacemakers.
 
Meanwhile, during the congress, MicroPort® displayed several innovative products such as Firehawk®, VitaFlow™, Columbus® and domestically made pacemakers in a booth jointly set up by MicroPort®, Shanghai MicroPort EP MedTech Co., Ltd. and MicroPort Sorin CRM (Shanghai) Co., Ltd. to demonstrate its innovation capabilities, which was highly recognized by people in attendance.
 
The GW-ICC is committed to promoting the cardiology development in China and raising cardiology research and prevention to a new level by engaging in international cooperation, knowledge promotion, academic exchange and crossover studies. As a leading high-end medical device company in China, MicroPort® will stick to innovation and continue to enhance its innovation capability to further promote the interventional treatment in China.